title: Beta-blockers and weight change in patients with chronic heart failure.
abstract: BACKGROUND
  There is an inverse association between body mass and mortality in patients with chronic heart failure (CHF). Beta-blockers have been associated with weight gain. We wanted to examine the relation between beta-blocker use and weight in a population of patients with CHF.
  
  
  RESULTS
  We weighed 276 patients presenting with CHF (mean age 71.3 ± 9.5 years, 72.8% male). None were taking a beta-blocker at presentation, but all had started by 4 months' follow-up. The patients were reweighed after 1 year. There was an increase in weight (0.9 ± 7.0 kg; P = .03) and body mass index (0.2 ± 2.4 kg/m(2); P = .02). Patients in New York Heart Association (NYHA) functional class III or IV had no significant weight change, whereas those in class I or II had an increase of 1.62 kg (P < .0001). In patients who had no peripheral edema at baseline or 1 year, there was a greater increase in weight (1.3 ± 6.9 kg; P = .01).
  
  
  CONCLUSIONS
  Beta-blocker use and intensification of heart failure treatment is associated with weight gain in CHF. The increase is greater in those who are nonedematous and tends to occur in patients with NYHA functional class I and II symptoms.
authors.affiliation: Department of Cardiology, Hull York Medical School, University of Hull, Kingston-upon-Hull, United Kingdom.
authors.forename: Ben W J
authors.initials: BW
authors.lastname: Boxall
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Clark
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D015331:Cohort Studies; D004487:Edema / Q000139:chemically induced / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists